Neisseria Meningitidis Infection - 25 Studies Found Status Study Completed Study Name: One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Condition: Meningococcal Disease Date: 2010-06-04 Interventions: Biological: rMenB+OMV NZ Subjects will be assigned to a study group based on the group assignment in the Completed Study Name: Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Condition: Meningococcal Disease Date: 2009-02-18 Interventions: Biological: 1a - rMenB+OMV NZ and routine vaccines Completed Study Name: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Condition: Meningococcal Disease Date: 2014-05-06 Interventions: Biological: MenABCWY Effective Completed Study Name: Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Condition: Meningococcal Disease Date: 2008-04-16 Interventions: Biological: rMenB+OMV NZ Other Completed Study Name: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine Condition: Meningococcal Disease Date: 2009-12-04 Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vacc Completed Study Name: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine Condition: Meningococcal Disease Date: 2009-12-04 Interventions: Biological: rMenB Biological: rMenB+OMV NZ Completed Study Name: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Condition: Prevention of the Meningococcal Disease Date: 2013-07-26 Interventions: Biological: rMenB+OMV NZ Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain Completed Study Name: Correlation Between Cytokines and the Severity of Meningococcal Disease Condition: Meningococcemia Date: 2010-05-27 Recruiting Study Name: South Australian Meningococcal B Vaccine Herd Immunity Study Condition: Meningococcal Disease Date: 2017-03-17 Interventions: Biological: Licensed 4CMenB vaccine Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month t Recruiting Study Name: PRIME Follow up - Quadri Meningo Vacinees Condition: Meningococcal Disease Date: 2016-06-15 Interventions: Other: venepuncture only single venepuncture <<< Previous | Next >>>